Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Benelux Stocks: Imtech, Pharming and Unit4 Shares Are Active

June 24 (Bloomberg) -- The Amsterdam Exchanges Index retreated 5.89, or 1.8 percent, to 329.22, a third straight drop. Belgium’s Bel20 Index declined 38.54, or 1.6 percent, to 2,455.80.

The following are among the most active stocks in the Benelux markets today. Symbols are in parentheses.

Dutch stocks:

Imtech NV (IM NA) fell 5.3 percent to 22.08 euros, a third day of declines. The largest Dutch technical-services company agreed to buy Sweden’s NEA Gruppen AB for about 975 million kronor ($125 million) and said it will sell as many as 8.32 million shares, partly to help finance the purchase.

Pharming Group NV (PHARM NA) surged 13 percent to 27 eurocents, the highest level in almost a month. The Dutch biotechnology company that uses the milk of genetically modified rabbits to make medicines said in European regulators approved its Rhucin drug.

Unit4 NV (UNIT4 NA) dropped 3 percent to 17.89 euros. The largest Dutch distributor of software for accounting firms will await Teta SA’s results in the current quarter before deciding on whether to raise its bid for the company, Het Financieele Dagblad reported, citing Chief Financial Officer Edwin van Leeuwen. Unit4 has room to raise its bid, Van Leeuwen is quoted as saying.

To contact the reporter on this story: Maud van Gaal in Amsterdam at

To contact the editor responsible for this story: David Merritt at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.